Neurovance Receives $5,499,459 New Funding

  • Feed Type
  • Date
    3/26/2015
  • Company Name
    Neurovance
  • Mailing Address
    43 Thorndike Street Cambridge, MA 02141 USA
  • Company Description
    Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
  • Website
    http://www.neurovance.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,499,459
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy